The FDA told Lundbeck that promotional claims for Vyepti (eptinezumab-jjmr) — including “100% migraine freedom for a month or more” — are unsupported by the cited PREVAIL and PROMISE trial analyses, saying the post-hoc data lacked prespecified controls for false positives. In a warning letter, the agency said those limitations make it impossible to determine whether the reported benefit was due to Vyepti or chance.

Why It Matters To Oncology

• For oncology drug developers, the letter is a reminder that regulators are scrutinizing how companies translate subgroup, exploratory, and post-hoc analyses into promotional claims.

• That matters especially in cancer, where accelerated approvals, biomarker-defined subsets, and long-tail response narratives can create pressure to overstate durability or depth of benefit beyond what prespecified analyses support.

• The FDA’s focus on “attention-grabbing” presentation also signals that enforcement risk extends beyond the data itself to how efficacy messages are framed for clinicians and patients.

The Financials

• No financial penalty was disclosed in the letter, but the FDA asked Lundbeck to take immediate corrective action and explain how it will discontinue or revise the challenged materials.

• Commercially, promotional restrictions can affect brand messaging, field-force execution, and lifecycle strategy for established specialty products.

• Separately in the same news cycle, AstraZeneca preserved a major legal win for Tagrisso, which posted about $7.3 billion in global sales last year, after a US appeals court upheld invalidation of the asserted Wyeth patents.

What They're Saying

• The FDA said there were “significant limitations” in the cited references that “preclude the drawing of conclusory claims regarding the benefits of Vyepti.”

• On the month-long migraine-freedom claim, the agency said that without prespecified statistical controls, “it is not possible to ascertain whether the findings were attributable to treatment with Vyepti, or merely due to chance.”

• The agency also objected to the use of bold, colorful graphics on the “Real VYEPTI experience” webpage that it said amplified disputed efficacy claims.

What's Next

• Lundbeck will need to respond to the FDA with a plan to stop or correct the cited communications.

• Clinicians and oncology commercial teams should expect continued regulatory attention on digital promotion that leans on exploratory analyses without clear statistical guardrails.

• For drug discovery and development groups, the broader takeaway is to align evidence-generation, medical affairs, and marketing early — especially when trying to convert nuanced trial readouts into simple clinical claims.